Use of condensed benzo[b]thiazine derivatives as cytoprotectants

A method of treating a condition where elimination of lipid hydroperoxides and/or limiting their detrimental effects on cellular macromolecules is desired and/or a disease or state, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body, comprising administering an effective amount of one or more compound(s) of formula (I)

• wherein (i) G1, G2, G3, and G4 are each C or N, provided that at least one of G1, G2, G3, and G4 is C;
• (ii) G7 is C(R7)2;
• and
• (iii) G8 is [CH2]kC(R8)2, C(R8)2CH2, C(R8)2C(R8)2, [CH2]2, or (C═O);
• whereby
• each R1 is independently selected from a group consisting of halogen, cyano, nitro, OR′, C1-6-(per)haloalkoxy, N(R′)2, SR′. SOR′, SO2R′, C1-6-alkyl, C1-6-(per)haloalkyl, COOR′, and CON(R′)2;
• and/or two adjacent R1 together with the ring atoms they are attached to form a 5 to 7 membered ring optionally comprising 1 to 3 heteroatoms selected from N, O, and S;
• each R5 is independently selected from a group consisting of halogen, cyano, nitro, OR′, oxo, C1-6-(per)haloalkoxy, N(R′)2, C1-6-alkyl, C1-6-(per)haloalkyl, COOR′, CON(R′)2;
• —[CH2]kAr, and C1-3-alkyl-(C═O)—;
• each R6 is independently selected from a group consisting of H, C1-6-alkyl, C1-6-(per)haloalkyl, C2-6-alkenyl, C2-6-alkynyl, OR′, N(R″)2, C1-3-alkyl-(C═O)—, C1-3-alkyl-(C═O)—NH—, —[CH2]kAr, and —[CH2]kCy;
• each R7 is independently selected from a group consisting of H, C1-6-alkyl, C1-6-(per)haloalkyl, OR″—C1-3-alkylenyl, N(R′)2-C1-3-alkylenyl, (R′)2NCO—C1-3-alkylenyl, COOR′, —[CH2]kAr, and —[CH2]kCy;
• or two R7 attached to a same ring carbon form together with the said ring carbon a 3 to 7 membered aliphatic carbocyclic or heterocyclic ring optionally substituted one or two times with R5;
• each R8 is independently C1-6-alkyl, or C1-6-(per)haloalkyl;
• or two R8 together with the ring carbon they are attached to form a 3 to 7 membered aliphatic or heteroaliphatic ring optionally substituted one or two times with R5;
• or one R7 and one R8 located on G7 and G8, respectively, form together a further bond between G7 and G8;
• and the other R7 and the other R8 are each independently H or as defined above or form together with the ring carbons they are attached to a 5 to 7 membered unsaturated carbocyclic or heterocyclic ring optionally substituted one or two times with R5;
• or one R7 and one R8 located on G7 and G8, respectively, form together with the ring carbons they are attached to a 3 to 7 membered aliphatic carbocyclic or heterocyclic ring optionally substituted one or two times with R5;
• and the other R7 and the other R8 are each H;
• each R′ is independently H or C1-6-alkyl;
• or when attached to N each R′ may alternatively be C1-3-alkoxy-C1-3-alkylenyl, or two R′ may form together with the N they are attached to a 5 to 6 membered saturated heterocyclic ring optionally comprising one further heteroatom selected form N, O and S;
• each R″ is independently selected group a group consisting of R′, CN—C1-3-alkylenyl, C1-3-alkoxy-C1-3-alkylenyl, C1-6-alkenyl, C1-6-alkynyl, and C1-3-alkyl-(C═O)—;
• or each R″ forms together with a R7 or R8, respectively, an C-alkylene bridge;
• Ar is phenyl or 5 to 6 membered aromatic heterocyclic ring comprising one, two or three N atoms, said phenyl or ring being optionally substituted one or two times with R5;
• Cy is 3 to 7 membered aliphatic carbocyclic or heterocyclic ring optionally substituted one or two times with R5;
• i is 0, 1, or 2;
• k is 0 or 1;
• m is 0, 1, 2, 3, or 4;
• n is 0, 1, 2, or 3;
• or metabolite, N-oxide, pharmaceutically acceptable salt, hydrate, or solvate thereof to a patient in need thereof.